A microscopic parasite that can steal human sight has long evaded medicine's best efforts, partly because so little was known about its inner workings. Researchers at the University of Wisconsin have now charted the complete protein landscape of Acanthamoeba's energy-producing core, revealing more than 300 molecular structures found nowhere in the human body — potential footholds for treatments that could spare patients without harming them. The work is less a cure than a map: a precise accounting of where, in the architecture of a dangerous organism, medicine might finally find purchase.
Proteomics reveals metabolic vulnerabilities in eye-infecting Acanthamoeba parasite
Acanthamoeba infections can cause sight-threatening keratitis and corneal damage, with limited effective treatment options available.
Metabolic flexibility may help it persist where current drugs cannot reach.
Mark
So this is about an amoeba that infects eyes. How common is that actually?
Mimi
Acanthamoeba is everywhere—water, soil, air—but eye infections are rare. When they do happen, though, they're serious. We're talking sight-threatening corneal damage. The real problem is that once you get infected, the treatments available are toxic and don't work that well.
Luke
The source says the infections are rare but doesn't give numbers. We don't actually know how many cases occur per year or what the mortality or vision-loss rate is. That context would matter.
Mark
What did the researchers actually discover here?
Mimi
They mapped all the proteins in the amoeba's mitochondria—the energy-producing part of the cell. They found 1,122 proteins total, and about 300 of them don't exist in human mitochondria. That's important because it means you could potentially design a drug that targets something unique to the parasite without harming the patient.
Luke
But they didn't discover a drug. They created a catalog. That's foundational work, which is valuable, but it's not a treatment yet. The source is clear about that, but it's worth saying plainly: this is a map, not a cure.
Mark
Why does oxygen matter so much?
Mimi
When oxygen is available, the amoeba uses normal aerobic metabolism. But when oxygen runs low—which might happen inside a cyst or in certain tissues—it switches to a completely different pathway and actually produces hydrogen gas instead. That flexibility is probably why it's so hard to kill.
Luke
The source shows that the researchers demonstrated this in cells derived from eye infections, which is good evidence. But we don't know yet whether blocking that hydrogen-producing pathway would actually kill the organism or just slow it down.
Mark
So what happens next?
Mimi
Stefely and his team will start testing which of these unique proteins are actually essential for the amoeba's survival or for forming cysts. They'll work through them systematically, looking for the most promising drug targets.
Luke
That's years of work ahead. The source doesn't promise a timeline, and it shouldn't. This is the beginning of a search, not the end of one.
Il Polso
- Acanthamoeba keratitis can destroy corneal tissue and vision, yet the drugs used against it are blunt, toxic, and increasingly outmaneuvered when the parasite retreats into a drug-resistant cyst.
- A core obstacle was the organism's poorly understood genome — only half of its genes were accurately annotated, leaving researchers effectively blind to what proteins the parasite was actually producing.
- The team rebuilt that genetic blueprint from near-scratch, pushing annotation accuracy from 52% to 98%, then used six complementary laboratory techniques to catalogue every protein inside the amoeba's mitochondria.
- The resulting AcMitoCarta database — 1,122 proteins, over 300 unique to the organism — transforms the drug-discovery search from a vast guessing game into a focused, experimentally grounded investigation.
- A newly discovered oxygen-sensing metabolic switch, which lets the amoeba generate energy without oxygen at all, may explain its stubborn survival in the cornea and now stands as a potential target itself.
A microscopic parasite that can steal human sight has long evaded medicine's best efforts, partly because so little was known about its inner workings. Researchers at the University of Wisconsin have now charted the complete protein landscape of Acanthamoeba's energy-producing core, revealing more than 300 molecular structures found nowhere in the human body — potential footholds for treatments that could spare patients without harming them. The work is less a cure than a map: a precise accounting of where, in the architecture of a dangerous organism, medicine might finally find purchase.
A free-living amoeba that drifts through water and soil rarely troubles human health — until it reaches the eye. When Acanthamoeba castellanii infects the cornea, it can cause keratitis severe enough to threaten sight, and it does so with a biological flexibility that makes it maddeningly hard to eliminate. Current treatments damage human cells alongside the parasite, and once the organism retreats into a dormant cyst, even those imperfect options lose their grip.
Jon Stefely and his colleagues at the University of Wisconsin set out to understand the organism from the inside. Their focus was the mitochondria — the cellular engines that generate energy — because that is where the amoeba's survival strategies are encoded at the molecular level. But before they could study those proteins, they had to fix a more fundamental problem: the organism's genome was only about half accurately annotated. Using long-read RNA sequencing and related methods, the team rebuilt that blueprint, raising annotation accuracy from 52% to 98%. With a legible genome in hand, they deployed six laboratory techniques in combination — including mass spectrometry, microscopy, and density-gradient purification — to identify every protein present in the organelle.
The resulting catalog, AcMitoCarta, contains 1,122 mitochondrial proteins. More than 300 of them appear to be genuinely unique to Acanthamoeba, with no close counterpart in human or yeast cells. That divergence is precisely what drug developers need: a compound aimed at a protein that exists only in the parasite is far less likely to cause collateral damage to the patient. The catalog also uncovered a striking metabolic adaptation — when oxygen runs low, the amoeba activates an entirely different energy pathway, producing hydrogen gas instead. This flexibility, observed in cells taken from actual eye infections, may help explain how the organism persists despite treatment and the body's own defenses.
AcMitoCarta does not deliver a drug. What it delivers is a dramatically narrowed search space — a validated inventory of targets that researchers can now investigate in focused, systematic groups. Stefely describes the ambition plainly: annotate the function of every unique target, one small set at a time. For patients facing sight-threatening infections with few good options, that methodical work represents something medicine has not yet offered them — a genuinely promising place to begin.
A single-celled parasite that lives in water and soil has learned to survive in the human eye by rewiring its energy-producing machinery when oxygen runs low. Acanthamoeba castellanii, a free-living amoeba, rarely causes disease—but when it does infect the cornea, the results can be sight-threatening. The infection produces a condition called keratitis, and the organism's ability to adapt to different oxygen levels makes it stubbornly difficult to kill. Current treatments are blunt instruments: they work, sometimes, but they damage human cells in the process, and once the amoeba retreats into a drug-resistant cyst, options narrow further.
Jon Stefely, a metabolism researcher at the University of Wisconsin School of Medicine and Public Health, and his colleagues have now mapped the complete inventory of proteins operating inside Acanthamoeba's mitochondria—the cellular structures responsible for generating energy. The work, published in Cell as part of the MitoCarta Tree of Life Consortium, reveals not just how the organism survives, but where it might be vulnerable to attack. "Our current drugs are untargeted and toxic, and we just need more options for treating these infections," Stefely said. The lack of good diagnostics compounds the problem; by the time an infection is confirmed, the organism has already begun its defense.
The research began with a fundamental problem: the amoeba's genetic blueprint was incomplete and poorly annotated. Stefely's team improved the accuracy of the organism's nuclear genome annotation from roughly 52 percent to 98 percent using long-read RNA sequencing and other empirical methods. This matters because most mitochondrial proteins are encoded in the nucleus, not the mitochondria itself. Without knowing what genes actually code for what proteins, the researchers would be working blind. Once the genome was legible, they combined multiple techniques—mitochondrial immunoprecipitation, density-gradient purification, microscopy, mass spectrometry, and protein-correlation profiling—to isolate and identify every protein present in the organelle. Blue native PAGE–mass spectrometry further resolved twenty distinct macromolecular assemblies.
The resulting catalog, called AcMitoCarta, contains 1,122 proteins. Of these, 381 lack readily identifiable counterparts in human or yeast mitochondria. Just over 300 are genuinely unique to Acanthamoeba. That divergence is the key to better drugs. A compound designed to target a protein found only in the parasite is far less likely to harm human cells than one aimed at a pathway shared between the microbe and its host. "If you have a target protein in a biochemical pathway that's completely unique to the microbe, it's a better target than something that has a homolog in humans," Stefely explained.
The proteome also revealed how the organism shifts its metabolism in response to oxygen. Under normal oxygen-rich conditions, Acanthamoeba's mitochondria operate through standard aerobic pathways. But when oxygen becomes scarce—as it might in certain tissues or within a cyst—the organelles induce a different pathway entirely. They activate a pyruvate:ferredoxin oxidoreductase-to-hydrogenase system that allows the amoeba to generate hydrogen gas without oxygen. This metabolic flexibility, demonstrated in cells derived from actual eye infections, may explain how the organism persists in the cornea despite the body's defenses and despite treatment attempts.
The catalog does not yet point to a ready-made drug. What it does is narrow the search space dramatically. Instead of hunting through thousands of proteins, researchers can now focus on experimentally validated mitochondrial components and pathways that differ from those in humans. Stefely plans to investigate candidates in focused groups, working with collaborators in mass spectrometry, RNA sequencing, metabolism, structural biology, and imaging. "A long-term goal is to annotate functions for all of those targets," he said, "but we'll take them one small set at a time and there is a lot of potential for new discoveries."
The work represents a shift from incomplete guesswork to functional mapping. By moving from a fragmented genome annotation to a detailed picture of how Acanthamoeba's mitochondria respond to changing conditions, the researchers have created a foundation for developing treatments that are both more selective and more effective. For patients facing sight-threatening infections with few good options, that foundation may eventually mean the difference between vision preserved and vision lost.
Citazioni salienti
Our current drugs are untargeted and toxic, and we just need more options for treating these infections.— Jon Stefely, University of Wisconsin School of Medicine and Public Health
If you have a target protein in a biochemical pathway that's completely unique to the microbe, it's a better target than something that has a homolog in humans.— Jon Stefely
Vuoi la storia completa?
Leggi l'originale su Genetic Engineering and Biotechnology News ↗